Racial Disparities Persist in Breast Cancer for Women and Colorectal Cancer in Men
March 1st 2016Racial disparities in mortality for breast cancer have gotten worse in women and persisted for colorectal cancer in men, although progress has been made in closing the mortality gap between blacks and whites for other cancers.
Everolimus Approved for GI and Lung Neuroendocrine Tumors
February 29th 2016The FDA approved the mTOR inhibitor everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal or lung neuroendocrine tumors.
FDA Expands Palbociclib Approval to Include Pretreated HR+/HER2-Negative Breast Cancer
February 26th 2016Patients with pretreated, HR-positive, HER2-negative metastatic breast cancer can now receive palbociclib (Ibrance) for use in combination with fulvestrant following the FDA’s recent approval of this new indication for the CDK 4/6 inhibitor.
Too Much Imaging? Study Finds in Early-Stage Breast Cancer, the Answer is Yes
February 24th 2016A study involving nearly 30,000 patients diagnosed with early-stage breast cancer has found that up to 60% of these women received imaging tests such as CT, bone, and PET scans that were not medically justified, contrary to national guidelines.
Intervention Reduces Emergency Department Visits, Improves Patient Care
February 23rd 2016A telephone triage service combined with patient education has helped to reduce cancer-related emergency department visits by 60% over 4 months, where it was piloted at a Florida health system, and it’s an approach researchers say can be easily replicated by other practices.
Effort Launched to Increase HPV Vaccine Uptake
February 16th 2016Sixty-nine National Cancer Institute–designated cancer centers are urging parents, young adults, and healthcare providers to increase HPV vaccination rates, with only an estimate 40% of girls and 21% of boys in the United States receiving the recommended three doses of the HPV vaccine.
Young Adults With Cancer Need More Dialogue With Providers on Costs
February 15th 2016A paper in Cancer Medicine finds that cancer has a devastating and age-specific impact on the finances of young adult survivors, and increased dialogue between healthcare providers and YAs has the potential to empower this population at risk for adverse financial and psychosocial outcomes, and steer them towards reputable sources of financial support.
Myelofibrosis Drug Pacritinib Placed on Full Clinical Hold by FDA
February 15th 2016After reports of patient deaths related to intracranial hemorrhage, cardiac failure, and cardiac arrest in the phase III PERSIST-2 trial, the FDA has placed a “full clinical hold” on trials exploring the tyrosine kinase inhibitor pacritinib.
Single-Dose Emend for Injection Approved
February 5th 2016Fosaprepitant dimeglumine (Emend for injection) received FDA approval as a single-dose in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.